MDACC Study No:2013-0090 ( NCT No: NCT01880567)
Title:A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator:Michael Wang
Treatment Agent:Ibrutinib; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if a combination of
ibrutinib and rituximab can help control relapsed or refractory MCL. The safety
of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults